IMV IMV Inc.

2.95
-0.13  -4%
Previous Close 3.08
Open 3.03
Price To Book -98.33
Market Cap 178,340,698
Shares 59,829,854
Volume 212,352
Short Ratio
Av. Daily Volume 298,392
Stock charts supplied by TradingView

NewsSee all news

  1. Clinical Response and Translational Data from DeCidE1, a Phase 2 Study of DPX-Survivac Immunotherapy in Patients with Advanced Recurrent Ovarian Cancer

    Survivin-targeted T cell therapy continues to show significant, durable anti-tumor activity and is well-tolerated in this hard-to-treat cancer patient population 5/19 patients (26%) achieved a partial regression on

  2. IMV Announces Selection of a Vaccine Candidate Against COVID-19 to Advance Into Human Clinical Studies

    Majority of 23 peptide epitopes selected by IMV demonstrated robust antibody responses in an animal model after first and second dose in DPX formulation without any additional adjuvant DPX-COVID-19 to utilize

  3. IMV Inc. Provides Clinical and Operational Update and Announces First Quarter 2020 Financial Results

    Phase 2 SPiReL study of DPX-Survivac combination regimen with Keytruda® in r/r DLBCL successfully reached primary efficacy endpoint with 64% (7/11) of evaluable patients demonstrating a clinical

  4. IMV Inc. Announces Closing of $25.1 Million Private Placement

    IMV Inc. ("IMV" or the "Company") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious diseases including

  5. IMV Inc. to Announce First Quarter 2020 Results and Host a Conference Call and Webcast on May 15, 2020

    IMV Inc. ("IMV" or the "Corporation") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious diseases including

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data due 2020.
DPX-Survivac and pembrolizumab
Diffuse Large Cell Lymphoma
Phase 2 updated data at ASCO May 29, 2020. 5/19 patients (26%) achieved a PR with tumor regression.
DPX-Survivac and epacadostat (DeCidE1)
Ovarian cancer
Phase 2 trial ongoing.
DPX-Survivac and pembrolizumab
Ovarian cancer
Phase 2 top-line data due 2H 2020.
DPX-Survivac and KEYTRUDA (pembrolizumab) - basket trial
Solid tumors
Phase 1 dosing has commenced - January 17, 2019.
DPX-NEO - neoepitopes
Ovarian cancer
Phase 1 trial to be initiated summer of 2020.
DPX-COVID-19
Coronavirus COVID-19
Phase 1 trial to commence summer 2020.
DPX-COVID-19
COVID-19

Latest News

  1. Clinical Response and Translational Data from DeCidE1, a Phase 2 Study of DPX-Survivac Immunotherapy in Patients with Advanced Recurrent Ovarian Cancer

    Survivin-targeted T cell therapy continues to show significant, durable anti-tumor activity and is well-tolerated in this hard-to-treat cancer patient population 5/19 patients (26%) achieved a partial regression on

  2. IMV Announces Selection of a Vaccine Candidate Against COVID-19 to Advance Into Human Clinical Studies

    Majority of 23 peptide epitopes selected by IMV demonstrated robust antibody responses in an animal model after first and second dose in DPX formulation without any additional adjuvant DPX-COVID-19 to utilize

  3. IMV Inc. Provides Clinical and Operational Update and Announces First Quarter 2020 Financial Results

    Phase 2 SPiReL study of DPX-Survivac combination regimen with Keytruda® in r/r DLBCL successfully reached primary efficacy endpoint with 64% (7/11) of evaluable patients demonstrating a clinical

  4. IMV Inc. Announces Closing of $25.1 Million Private Placement

    IMV Inc. ("IMV" or the "Company") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious diseases including

  5. IMV Inc. to Announce First Quarter 2020 Results and Host a Conference Call and Webcast on May 15, 2020

    IMV Inc. ("IMV" or the "Corporation") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious diseases including

  6. Vaccine Candidate to Prevent COVID-19: Fonds de solidarité FTQ to Invest $7.5 Million in IMV

    QUÉBEC CITY, April 30, 2020 /CNW Telbec/ - The Fonds de solidarité FTQ (the "Fonds" will invest $7.5 million in IMV Inc. ("IMV") (NASDAQ:IMV); (TSX:IMV) to support the development of highly innovative

  7. IMV Announces Proposed $22.3 Million Private Placement

    IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company, today announced its intention to complete a private placement (the "Private Placement") of 7,797,203 units of the Company (each, a "Unit") at

  8. IMV to Participate in Adelaide Capital's Virtual COVID & Healthcare Mini Conference

    IMV Inc. (NASDAQ:IMV, TSX:IMV) a clinical-stage biopharmaceutical company, today announced that Company's management will be participating in Adelaide Capital's Virtual COVID & Healthcare Mini Conference on April

  9. IMV Inc. Announces Fourth Quarter and Full Year 2019 Financial and Operational Results

    Launched development program for a DPX-based vaccine candidate against COVID-19 Reported updated Phase 2 data from DeCidE1 study in advanced ovarian cancer; These encouraging results support DPX-Survivac being

  10. IMV Inc. Provides Updates on the Development of DPX-COVID-19 Vaccine and Ongoing Business and Clinical Operations

    IMV Inc. (NASDAQ:IMV) (TSX:IMV), a clinical-stage biopharmaceutical company (the "Company" or "IMV"), today provided updates on the development of DPX-COVID-19, a vaccine candidate against the novel coronavirus, and on

  11. IMV to Announce Fourth Quarter and Full Year 2019 Financial and Operational Results and Host Investor Conference Call and Webcast on March 31, 2020

    IMV Inc. ("IMV" or the "Corporation") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, announced today that it will hold a conference call and webcast on

  12. IMV Inc. Establishes At-the-Market Facility

    IMV Inc. (TSX:IMV, NASDAQ:IMV) (the "Company" or "IMV"), a clinical-stage biopharmaceutical company, today announced that it has entered into an equity distribution agreement, dated March 18, 2020, with Piper

  13. IMV Inc. Launches Plans to Advance Clinical Development of a Vaccine Candidate Against COVID-19

    IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company (the "Company" or "IMV"), today announced that it is advancing the clinical development of a DPX-based vaccine candidate against COVID-19.

  14. IMV Inc. Announces Breakthrough Data from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac in Patients with Advanced Recurrent Ovarian Cancer

    First in-vivo T cell therapy to demonstrate clinical activity in hard-to-treat solid tumor 79% of evaluable patients achieved disease control on target lesions; 53% experienced tumor regressions 37% achieved durable

  15. IMV to Host Conference Call & Webcast to Report Updated Results from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac in Patients with Advanced Recurrent Ovarian Cancer

    IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that company management will host a conference call & webcast to report topline

  16. IMV Announces Board Retirement

    IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that Albert Scardino will retire from the IMV Board of Directors effective February

  17. Clinical Translational Data Supporting DPX-Survivac Mechanism of Action to be Presented at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium

    DPX-Survivac generated strong, sustained and functional survivin-specific T cell response in 80% of patients' blood samples Clinical anti-tumor responses were correlated with increased infiltration of T cells into

  18. IMV to Present at 2020 BIO CEO & Investor Conference

    IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that company management will present at the BIO CEO and Investor Conference on

  19. IMV to Host Key Opinion Leader Symposium on Role of Survivin in Cancer Biology and Potential of DPX-Survivac

    IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that it will host a key opinion leader symposium on the role of survivin in cancer

  20. Updated Clinical Data from Phase 2 SPiReL Study Evaluating DPX-Survivac as a Combination Therapy in r/r DLBCL Presented at 61st American Society of Hematology (ASH) Annual Meeting

    7/9 (77.8%) evaluable subjects exhibited clinical benefit, including three complete responses and two partial responses Reproducible survivin-specific T cell responses and favorable safety profile observed in all

  21. IMV to Participate at Two Upcoming Investor Conferences

    IMV Inc. ("IMV" or the "Corporation") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that the IMV's executive management team will

  22. IMV Inc. Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    Reported preliminary data from Phase 2 basket study of DPX-Survivac in multiple solid tumors at the ESMO annual meeting, showing treatment was well-tolerated and showed signs of clinical activity Entered into

  23. Navidea Biopharmaceuticals Announces Preclinical Therapeutic Research Collaboration with IMV Inc. to Explore the Potential Combinatory Effect with Their Platform-Based Immunotherapies

    Navidea Biopharmaceuticals, Inc. (NYSE:NAVB), a company focused on the development of precision immunodiagnostics and immunotherapeutics, and IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical stage biopharmaceutical company

  24. IMV to Present Clinical Translational Data from DeCidE1 Study of DPX-Survivac at SITC 2019 Annual Meeting

    Robust survivin-specific T cell responses observed in recurrent late-stage ovarian cancer in nearly all evaluable subjects Survivin-specific T cells remain active and proliferative over time, leading to T cell

  25. IMV Appoints Joanne Schindler, M.D., D.V.M. as Chief Medical Officer

    IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced the appointment of Joanne Schindler, M.D., D.V.M. as its new Chief Medical Officer,

  26. IMV Inc. to Announce Third Quarter 2019 Results and Host a Conference Call and Webcast on November 8, 2019

    IMV Inc. ("IMV" or the "Corporation") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, announced today that it will hold a conference call and webcast on

  27. IMV Inc. to Present at Upcoming Investor Conference

    IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical stage immuno-oncology company, today announced that company management will be attending the BIO Investor Forum to be held on October 22-23 at the Westin St. Francis, San

  28. Preliminary Results From IMV's Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients With Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress 2019

    Tumor regressions and partial responses observed in subjects with ovarian, non-small cell lung and bladder cancer Treatment well-tolerated, with no related Grade 3-4 or immune-related adverse events IMV Inc.

  29. Preliminary Results From IMV's Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients with Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress 2019

    IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical stage immuno-oncology company, today announced that preliminary results from its ongoing Phase 2 basket trial, evaluating DPX-Survivac in combination with Merck's Keytruda®

  30. IMV Announces Research Collaboration with The Wistar Institute to Develop New Targeted Immunotherapy Against the Common BRAF Cancer Mutation

    IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage immuno-oncology company, today announced a collaboration with The Wistar Institute and Meenhard Herlyn, D.V.M., D.Sc., professor in the Molecular and Cellular Oncogenesis

  31. IMV Inc. to Present at Upcoming Investor Conferences

    IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical stage immuno-oncology company, today announced that company management will be presenting at the following investor conferences in September: Wells Fargo 14th Annual